Project Details
Description
KD025-209: A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis
Status | Active |
---|---|
Effective start/end date | 11/8/19 → 11/30/24 |
Funding
- KADMON CORPORATION, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.